Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome

INM004 showed an adequate safety profile. Efficacy non-statistically significant trends suggesting a beneficial effect in the amelioration of kidney injury were observed. These results encourage the conduction of a phase 3 study of INM004 in pediatric patients with STEC-HUS.

Authors

Institutions

Publication Details

Journal
Pediatric Nephrology
Published
2024-11-11
DOI
https://doi.org/10.1007/s00467-024-06583-3
Citations
10
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
2.40
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome

Ian Roubicek, Iliana Principi, Laura Alconcher, Vanesa Zylberman et al.
10 citations
Pediatric Nephrology
Complement system in diseases
2.40
article

Open-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli–associated hemolytic uremic syndrome

Ian Roubicek, Iliana Principi, Laura Alconcher, Vanesa Zylberman, Oscar Amoreo, Alejandro Balestracci, María Laura Flores Tonfi, Marta Rivas, Flavia Ramírez, Ana Paula Spizzirri, Claudia Seminara, Lidia Ghezzi, Linus Spatz, Santiago Sanguineti, Jorge Montero, Mariana Pichel, Pablo Bonany, Ángela Suárez, Luis Flynn, Mariana Colonna, Carolina Massa, María Carolina Bettendorff, Paula Coccia, Marina P. Valerio, Fernando A. Goldbaum, Alicia Fayad, María Valeria Blumetti, Marta Adragna
article en
10 citations

Abstract

INM004 showed an adequate safety profile. Efficacy non-statistically significant trends suggesting a beneficial effect in the amelioration of kidney injury were observed. These results encourage the conduction of a phase 3 study of INM004 in pediatric patients with STEC-HUS.

Pediatric NephrologyVol. 40(6)
Consejo Nacional de Investigaciones Científicas y Técnicas (AR), Garrahan Hospital (AR), Hospital Italiano de Buenos Aires (AR), Hospital Pedro de Elizalde (AR), Centro Científico Tecnólogico - Rosario (AR), Infant Foundation (AR), Helios Salud (AR), Asociación por los Derechos Civiles (AR), Hospital de Niños Superiora Sor María Ludovica (AR), Hospital de Niños de la Santísima Trinidad (AR), Hospital El Cruce (AR), Instituto de Neurología de Buenos Aires (AR), Hospital General de Niños Ricardo Gutierrez (AR), Fundacion Allende (AR), Universidad Nacional del Comahue (AR)
Good health and well-being
Openalex Percentile: Top 11%
Complement system in diseases
2.40
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.